Reversal of Tumour Drug Resistance with Monoclonal Antibodies
Emergence of drug resistance is a major problem in cancer chemotherapy. P-glycoprotein, a product of the MDR1 gene, plays an important role in multidrug resistance. Since P-glycoprotein is expressed on the tumour cell surface, therapeutic application of monoclonal antibodies (mAbs) against P-glycoprotein has been considered. Anti-P-glycoprotein mAbs enhance immune responses against multidrug-resistant tumours expressing P-glycoprotein, and also inhibit the transport function of P-glycoprotein. Accordingly, selective elimination of multidrug-resistant tumours has been demonstrated in vitro and in vivo. Although there remain many questions to be solved, selective targeting of multidrug-resistant tumours by anti-P-glycoprotein mAbs is a promising strategy for overcoming multidrug resistance.
KeywordsAdis International Limited Multidrug Resistance Vinca Alkaloid Anti Tumour Drug Multidrug Transporter
Unable to display preview. Download preview PDF.
- 16.Cenciarelli C, Currier SJ, Willingham MC, et al. Characterization by somatic cell genetics of a monoclonal antibody to the MDR1 gene product (P-glycoprotein): determination of P-glycoprotein expression in multi-drug-resistant KB and CEM cell variants. Int J Cancer 1991; 47: 533–43PubMedCrossRefGoogle Scholar